We are happy to share great news! SUL-238 is currently in Phase I clinical trials in collaboration with our Turkish partner GEN Ilac. It is the first drug reported that leads to persisting improvement of vascular aging. This work has recently been published in The Journal of Cardiovascular Aging. Cardiovascular diseases are a major cause of mortality worldwide and aging is primary risk factor for their development. SUL-238 specifically targets the mitochondria, which are the “powerhouses” of cell, and improve their function during disease. The study, performed by Annika Jüttner, dr. Anton Roks and co-authors from the department of Internal Medicine at the Erasmus University Medical Center Rotterdam, found that SUL-238 alleviates features of vascular aging and has a beneficial effect on aging in general. The researchers are hopeful that it could be a promising new treatment option to combat vascular aging.
SUL-238 improved vascular function and reduced inflammatory markers in the kidney
In this study SUL-238 was tested in a mouse model with a vascular-selective knockout of the endonuclease Ercc1 gene in vascular smooth muscle cells. Endonuclease is involved in the repair of DNA damage and defect in this gene accelerate aging. Accordingly, the mouse model specifically develops allerated aging in the vasculature, and this leads to problems in organs such as the brain, heart and kidney. Mice were treated chronically for 10 weeks and throughout the study vascular function was investigated. Treatment with SUL-238 restored endothelium-dependent vasodilation and prevented arterial stiffening in aortic and mesenteric arteries compared to vehicle treatment. Furthermore, treatment with SUL-238 reduced mRNA expression of inflammatory and damage markers in the kidney.
More information
The new publication is available through this link, would you like to receive more information about our compounds or discuss possibilities? Please contact us, we are happy to answer your inquiry!